CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment Elaborately Engineering a Self-Indicating Dual-Drug Nanoassembly for Site-Specific Photothermal-Potentiated Thrombus Penetration and Thrombolysis

Clinical TrialMarch 17, 2019

JOURNAL:N Engl J Med. Article Link

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers

DL Bhatt, CV Pollack, JS Lee et al. Keywords: Ticagrelor reversal; oral P2Y12 inhibitor; major bleeding

FULL TEXT PDF